2) The expert faculty for this symposium was led by program chair @alantanmd Director of GU Medical Oncology @RushMedical, along with @AlanBryce9 of @MayoCancerCare @MayoClinic, & #MahaHussein MD of @NorthwesternMed. The program can be reviewed in π½οΈat https://t.co/IzMFfDv9Av. pic.twitter.com/A0Uj8PcCPm
— @onc_ce (@onc_ce) August 3, 2023
4) Check out https://t.co/ZaDRkKS5ZH & earn 0.75h CE/#CME from a summary of the symposium.
— @onc_ce (@onc_ce) August 3, 2023
In this bonus #tweetorial, @alantanmd will "continue the conversation" from the #AACR23 symposium with an instructive case study and an update on π data released since AACR.
5b) Timeline ποΈ:
— @onc_ce (@onc_ce) August 3, 2023
πADT+salvage RT 9/2021-12/2021
π6/2022 PSA 3.34, testosterone 253
π Started abiraterone/prednisone for metastatic HSPC
π 1/2023 CT increasing nodes, PSAs 6.24, testosterone <13 pic.twitter.com/4bfjQ2j5FR
6b) The correct answer is c, #NGS, and that yields a #BRCA2 mutation. What is the next appropriate treatment?
— @onc_ce (@onc_ce) August 3, 2023
a. #Enzalutamide + #talazoparib
b. Enzalutamide
c. #Apalutamide + #Olaparib
d. Lu177 PSMA #radioligand therapy
7a) #PROpel was a Ph 3 trial in 1L #mCRPC comparing #abiraterone + the #PARPi #olaparib vs. abiraterone + placebo, with a primary endpoint of #rPFS.
— @onc_ce (@onc_ce) August 3, 2023
See https://t.co/90e1HsE9Aw pic.twitter.com/QLkmVSYSrC
7c) The trial met its primary endpoint of #rPFS in the intention to treat #ITT population.
— @onc_ce (@onc_ce) August 3, 2023
The most significant benefit was seen in #HRRm patients, specifically if #BRCA mutated. pic.twitter.com/JOVTXOLp8n
8) On May 31, 2023, @US_FDA approved #olaparib with #abiraterone & prednisone for adult patients with deleterious or suspected deleterious BRCA-mutated (#BRCAm) metastatic castration-resistant prostate cancer (#mCRPC), as determined by an FDA-approved companion diagnostic test. pic.twitter.com/fMbtOxd5Ob
— @onc_ce (@onc_ce) August 3, 2023
9b) The OS HR in these pts was 0.30 (95% CI: 0.15, 0.59). In the 711 patients (89% of ITT population) without #BRCAm, the #rPFS HR was 0.77 (95% CI: 0.63, 0.96) and the OS HR was 0.92 (95% CI: 0.74, 1.14).
— @onc_ce (@onc_ce) August 3, 2023
10a) #MAGNITUDE was another #PARPi combination trial: #niraparib + #abiraterone/prednisone (#AAP) vs. placebo and AAP. While some compare this study to #PROpel, it is important to understand that the study designs were vastly different. pic.twitter.com/t3senSNO6R
— @onc_ce (@onc_ce) August 3, 2023
10c) Then, due to pre-specified futility analysis, the IDMC recommended stopping enrollment to the biomarker negative cohort due to lack of added efficacy and in the setting of increased toxicity. pic.twitter.com/R3nNHHstfh
— @onc_ce (@onc_ce) August 3, 2023
11a) #TALAPRO_2 studied another #PARPi, #talazoparib, in combination with #enzalutamide compared to placebo/enzalutamide. Patients were stratified by #HRR gene alteration status which was studied prospectively using tissue and #ctDNA. pic.twitter.com/Qhwin0bkP6
— @onc_ce (@onc_ce) August 3, 2023
11c) In an exploratory analysis by #BRCA mutation status, the hazard ratio for #rPFS in patients with BRCA-mutated #mCRPC (n=155) was 0.20 (95% CI: 0.11, 0.36) and, in patients with non-BRCAm HRR gene-mutated mCRPC, was 0.72 (0.49, 1.07). pic.twitter.com/Lt1cPJAxL2
— @onc_ce (@onc_ce) August 3, 2023
13) And that catches you up on the impressive data presented in advanced mgmt of #mCRPC at #AACR23! Thanks to @alantanmd for the updates. And YOU just earned YET ANOTHER 0.5hr πCE/#CME from @onc_ce. Claim your certificate at https://t.co/ebSpCLb8qI.
— @onc_ce (@onc_ce) August 3, 2023